T. P. Hughes, J. Kaeda, S. Branford, et al., “Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chr- onic Myeloid Leukemia,” New England Journal of Medicine, Vol. 349, No. 15, 2003, pp. 1423-1432. doi:10.1056/NEJMoa030513

has been cited by the following article:

• TITLE: Impact of the Normalized Copy Number of BCR-ABL Transcript upon Diagnosis on Prognosis in CML Patients Treated with Imatinib-Mesylate

  AUTHORS: Christophe Martinaud, Aurélie Mayet, Sophie Bousquet, Nathalie Beaufils, Jean Gabert, Sophie Raynaud, Marie-Joelle Mozziconacci

  KEYWORDS: Chronic Myeloid Leukemia, RQ-PCR, Normalized Copy Number, BCR-ABL

  JOURNAL NAME: Open Journal of Blood Diseases, Vol.1 No.2, December 5, 2011

  ABSTRACT: Quantification of the BCR-ABL transcript is recommended to follow-up CML patients treated by imatinib mesylate (IM). Results are expressed as a normalized copy number (NCN) of BCR-ABL. We studied a cohort of 98 CML patients under IM as a first treatment and monitored by RQ-PCR after 12, 18 and 24 months according to the European LeukemiaNet recommendations. Our results support the hypothesis of an independent correlation between BCR-ABL NCN at diagnosis and major molecular response at 18 and 24 months in an inverse relationship. We also highlighted the possibility to use the NCN at diagnosis as a warning at diagnosis, and may be useful to identify patients who could benefit of a more rigorous follow-up.